Search results
Showing 1201 to 1250 of 2052 results for work
Discontinued Reference number: GID-TAG410
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Discontinued Reference number: GID-HST10019
Discontinued Reference number: GID-QS10108
Discontinued Reference number: GID-TA10807
Discontinued Reference number: GID-TA10185
Discontinued Reference number: GID-TAG415
Serelaxin for the treatment of acute decompensated heart failure [ID673]
Discontinued Reference number: GID-TAG454
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Discontinued Reference number: GID-TA11005
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Discontinued Reference number: GID-TA10783
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued Reference number: GID-TA10869
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Discontinued Reference number: GID-TA10413
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
In development Reference number: GID-TA11163 Expected publication date: TBC
Phentermine with topiramate for the treatment of obesity and overweight [ID543]
Discontinued Reference number: GID-TAG439
Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued Reference number: GID-TAG482
Discontinued Reference number: GID-TA10318
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Discontinued Reference number: GID-TA10186
Discontinued Reference number: GID-TA10196
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued Reference number: GID-TA10228
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Discontinued Reference number: GID-TA10267
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
Discontinued Reference number: GID-TAG385
In development Reference number: GID-TA10589 Expected publication date: TBC
Discontinued Reference number: GID-TA10910
Discontinued Reference number: GID-TA10933
Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]
Discontinued Reference number: GID-TA10401
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
Discontinued Reference number: GID-TA10210
Irreversible electroporation for treating prostate cancer (HTG688)
Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.
View recommendations for HTG688Show all sections
In development Reference number: GID-TAG386 Expected publication date: TBC
Discontinued Reference number: GID-TA10567
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Discontinued Reference number: GID-TA10891
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued Reference number: GID-TA10259
Discontinued Reference number: GID-TA10512
Discontinued Reference number: GID-TA10583